Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Like other marijuana stocks, Tilray has struggled to rein in losses, while investors gauge the impact of the U.S. election. So, is Tilray stock a buy now?

Is Tilray Stock A Buy Right Now? Here's What Earnings, Charts Show

Aurora Cannabis

Canopy Growth

Cronos Group

GrowGeneration Corp

Village Farms International

The Dow passed 30,000 as investors looked forward to 2021.

Stock Markets Are Record-Bound; Marijuana Stocks Soar

Aphria

Curaleaf Holdings, Inc.

Shares of major cannabis stocks are soaring once again following the news that Joe Biden's transition has formally begun. The uptick is fueled by expectations that the incoming administration will loosen regulations, as well as more US states legalizing sales of recreational marijuana.

Cannabis stocks are rising again

HEXO Corp

Cannabis stocks are soaring higher on Tuesday as investors continue to prepare for a Joe Biden presidency that could benefit pot companies. The post Cannabis Stocks: Why ACB, TLRY, CGC, HEXO and CRON Are Soaring Today appeared first on InvestorPlace.

Cannabis Stocks: Why ACB, TLRY, CGC, HEXO and CRON Are Soaring Today

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that it has entered into privately negotiated exchange agreements with certain holders of its 5.00% Convertible Senior Notes due 2023 (the "Notes"). Pursuant to the exchange agreements, the Company will exchange approximately $72.9 million in aggregate principal amount of Notes plus accrued interest,

Tilray, Inc. Announces Agreement to Exchange an Additional $72.9 Million in Principal Amount of Its 5.00% Convertible Senior Notes Due 2023 for Common Stock

Tilray is at a crossroads. It's currently enjoying strong tailwinds from the broader marijuana rally, but TLRY stock's fundamentals are underwhelming.

Mediocre Q3 Earnings Cut Struggling Tilray Stock off at the Knees

Amplify Seymour Cannabis ETF

Green Thumb Industries Inc.

Innovative Industrial Properties

Amplify Alternative Harvest ETF

Altria

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

Constellation Brands

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Pure Cannabis ETF 

Stock Selection Matters (Podcast Transcript)

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that it has entered into a privately negotiated exchange agreement with a certain holder of its 5.00% Convertible Senior Notes due 2023 (the "Notes"). Pursuant to the exchange agreement, the Company will exchange approximately $124.3 million in aggregate principal amount of Notes plus accrued interes

Tilray, Inc. Announces Agreement to Exchange Approximately $124.3 Million in Principal Amount of Its 5.00% Convertible Senior Notes Due 2023 for Common Stock

Tilray beat on earnings in their latest results pushing up their stock; Revenues remain flat-to-lower over multiple quarters despite epic increases in Canadian cannabis retail sales.

Tilray: Will Raise Money Diluting Shares Sending Stock Lower

A few months ago, Tilray stock didn't look too hot. But with rising Covid-19 cases, will the narrative shift positively for TLRY?

Coronavirus May Lend a Helping Hand to Tilray Shares

The bullish case for cannabis company Tilray Inc (NASDAQ: TLRY) can no longer be justified after the company's third-quarter earnings report showed stalling momentum in international markets, according to Jefferies. The Tilray Analyst: Owen Bennett downgraded Tilray from Hold to Underperform and lowered the price target from $5.60 to $4.77.

Why Jefferies Is Losing Its Tilray Buzz

Arena Pharmaceuticals

FSD Pharma

Akerna Corp

OrganiGram Holdings Inc.

SNDL Inc.

cbdMD Inc

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch in the upcoming week.

11 Cannabis Stocks Making Moves While Riding the 'Green Wave'

They're kind of getting the cart before the horse.

Here's the Big Mistake Some Marijuana Stock Investors Are Making Right Now

TLRY stock skyrocketed on a Biden win. But with the stock now up 75%, is it too late to buy?

Politics Still Holds the Key to Tilray Cannabis

TLRY Stock: Voters in January Will Decide if Tilray Goes to $95 or $0

Why Aurora Cannabis, HEXO, and Tilray Stocks Just Crashed

Pot stocks have been trading higher on the heels of Joe Biden being announced as the 2020 presidential election winner. The five states that passed legalization for adult-use cannabis and medical cannabis also bolstered the market.

Stock Wars: Aurora Cannabis Vs. Tilray

Earnings are out, and what went up just came back down.

Why Aurora Cannabis, Canopy Growth, and Tilray Stocks Wilted This Morning

Tilray, Inc. (TLRY) CEO Brendan Kennedy on Q3 2020 Results - Earnings Call Transcript

Shares of Tilray (NASDAQ:TLRY) rose 5.9% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 96.00% over the past year to ($0.02), which beat the estimate of ($0.21).

Tilray: Q3 Earnings Insights

Tilray Inc. saw very little revenue growth from cannabis sales in a Monday earnings report, but narrowed its losses and promised adjusted profitability in the fourth quarter, sending shares higher in late trading after a staggering run-up in pot stocks on the heels of the U.S. election.

Tilray stock booms after pot company promises profit despite stagnant sales growth

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, reports financial results for the third quarter ended September 30, 2020. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “Our third quarter results demonstrate the significant progress we have made throughout the organization despite the unprecedented challen

Tilray, Inc. Reports 2020 Third Quarter Results

Trulieve Cannabis Corp.

The legality of cannabis can differ greatly, depending on where you live.

A State-by-State Look at Where Marijuana Is Legal

New York mulls legalizing weed, and marijuana investors cheer.

Why Marijuana Stocks Are Hopping on Friday

Shares of Aurora Cannabis have more than doubled since Election Day after several states voted to legalize some form of marijuana use.

Aurora Cannabis, other pot stocks surge as marijuana legalization spreads in the US

News for Tilray Brands Stock (TLRY)